NCT06251297Recruiting
Feasibility and Benefits of Reflexology in the Prevention of Neuropathy Induced by Oxaliplatin in Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 10 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The management of colorectal cancer often requires oxaliplatin-based chemotherapy, either as part of curative treatment plans or exclusively in palliative situations. Oxaliplatin therefore plays a key role in the management of colorectal cancer. In addition to its digestive and hematological toxicity, oxaliplatin frequently induces chronic, often limiting, sensitive peripheral neuropathy. Only early discontinuation of oxaliplatin can limit the risk of clinically limiting neurotoxicity (grade ≥ 3). In oncology, managing the side-effects of treatment is an essential objective of supportive care, and is open to a variety of complementary medicines, including reflexology. This technique, derived from traditional Chinese medicine, involves stimulating reflex points on the arch of the foot.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 25 Jan 2024
- Start date
- 29 Apr 2024
- Primary completion date
- 1 May 2026
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Colorectal cancer
- NCT number
- NCT06251297
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 29 Apr 2024 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindication to reflexology: venous thrombosis, trauma, wound or metastasis of the foot.
Other
- Pre-existing motor and/or sensitive neuropathy.
- Reflexology treatment within the last 6 months.
- Patient covered by a legal protection scheme.
Who the study is looking for
- Age\>18 years treated for colorectal cancer in Digestive Oncology service Rangueil hospital
- Initiation of intravenous oxaliplatin chemotherapy at 85 mg/m² on a bimonthly schedule.
- Ability to understand and answer a self-questionnaire.
- Life expectancy egal or over 12 weeks
- Signed informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.